Oxford Asset Management’s AbCellera Biologics ABCL Stock Holding History

Oxford Asset Management’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$244K	Buy	+31,064	New	+$152K	0.12%	262
2026 Q1	–	Sell	-14,875	Closed	-$50.9K	–	461
2025 Q4	$50.9K	Buy	+14,875	New	+$66.4K	0.02%	476
2025 Q2	–	Sell	-28,241	Closed	-$63K	–	512
2025 Q1	$63K	Buy	+28,241	New	+$81K	0.03%	448

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $38B AUM 39.14% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Oxford Asset Management's ABCL Position: Q2 2026 in Review

Oxford Asset Management opened a new position in AbCellera Biologics (ABCL) in Q2 2026: 31,064 shares worth $244K. The stake represents 0.12% of the portfolio and ranks #262 among its holdings. This is a return to the name: Oxford Asset Management previously reported a position in ABCL as recently as Q4 2025.

Oxford Asset Management first reported a position in ABCL in Q1 2025 and has held it in 3 quarters since. 150 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

Oxford Asset Management held 31,064 shares of AbCellera Biologics worth $244K as of Q2 2026.
AbCellera Biologics was a new Oxford Asset Management position in Q2 2026.
AbCellera Biologics made up 0.12% of Oxford Asset Management's portfolio in Q2 2026, its #262 holding.
Oxford Asset Management first reported a position in AbCellera Biologics in Q1 2025 and has held it in 3 quarters since.
150 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Oxford Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.